Stocks in play: BioVaxys Technology Corp

Announced today that it has entered into an agreement with Millipore-Sigma, a global Contract Development and Manufacturing Research Organization, to manufacture a supply of GLP-grade BVX-1021, the Company's newly developed vaccine for the strain of coronavirus that causes Severe Acute Respiratory Syndrome, the respiratory illness responsible for the deadly 2002–2004 pandemic. Currently there are no vaccines approved for SARS1. BioVaxys Technology Corp shares C.BIOV are trading down one cent at $0.12.

Read:

• Reducing the Risks of Adverse Reactions to Covid Vaccines May Also Reduce Hesitancy and Injuries

• Growing Plant-Based Protein Wholesalers Seizing Upon Market’s Appetite for Vegan Options

• Therapy Shake-Up Called for by Mental Health Experts Seeking Solutions for Mental Health Crisis

• Pharmacies and In-Clinic Testing Set to Remain as Covid-19 Numbers Shift into Post-Pandemic Phase

• Biotech Innovators Making Strides Towards Meeting Increased Demand for Breast Cancer Treatments